Can a new drug help when standard treatment fails for polycythemia vera?

This trial tests whether an experimental drug called bomedemstat can help people with polycythemia vera (a condition where the body makes too many red blood cells) who did not get better with or could not tolerate the common treatment hydroxyurea. Participants will receive either bomedemstat or one of two standard treatments (ruxolitinib or ropeginterferon alfa-2b). The study aims to see if bomedemstat leads to healthy blood cell counts and prevents serious complications like blood clots or disease progression.